S1P signalling inhibition by in vivo FTY720 (Fingolimod) treatment in RRMS patients leads to a decrease in IFNG and TBX21 gene expression [32] and increased expression of TIM‐3, a marker of highly suppressive Tregs [33], by Tregs. This evidence concerns the gene IFNG and relapsing-remitting multiple sclerosis.